Insul Glargine SC Injection 100 IU/ml is a long-acting insulin analog used in the management of diabetes mellitus. It is designed to provide a steady, baseline level of insulin over an extended period, helping to control blood glucose levels in patients with type 1 or type 2 diabetes. Insulin Glargine is produced through recombinant DNA technology, which allows for a consistent and predictable pharmacokinetic profile.
Insulin Glargine is used for:
| Brand Name | Insul Glargine |
|---|---|
| Type | SC Injection |
| Weight | 100 IU/ml |
| Generic | Insulin Glargine [rDNA] |
| Manufacturer | Popular Pharmaceuticals Ltd. |
| Available in | English বাংলা |
Insulin Glargine mimics the action of endogenous insulin by binding to insulin receptors on target cells, facilitating the uptake of glucose into cells and regulating glucose metabolism. It differs from human insulin in its amino acid sequence, which allows it to form microprecipitates in the subcutaneous tissue. This results in a slow and steady release of insulin into the bloodstream, providing prolonged blood glucose control.
Insulin Glargine begins to lower blood glucose levels within 1 to 2 hours after subcutaneous injection. Its peak effect is not sharply defined, but it maintains a consistent level of insulin activity for approximately 24 hours, making it effective for once-daily dosing.
Insulin Glargine is absorbed slowly from the subcutaneous tissue due to its formulation and the formation of microprecipitates. It has a relatively stable and consistent absorption profile, which contributes to its long duration of action.
Insulin Glargine is metabolized primarily in the liver, where it is converted to active metabolites. The insulin itself is not excreted directly but is broken down into smaller peptides and amino acids that are then excreted in the urine.
Adults:
Children:
Insulin Glargine is administered subcutaneously, typically once daily at the same time each day to maintain consistent insulin levels. It can be injected into the abdomen, thigh, or upper arm. It should not be mixed with other insulins or injected intramuscularly or intravenously.
Common side effects include hypoglycemia, weight gain, and injection site reactions such as redness, swelling, or itching. Less common side effects may include allergic reactions and lipodystrophy (changes in subcutaneous fat at the injection site).
Symptoms of overdose or excessive dosing of Insulin Glargine include severe hypoglycemia, which can lead to symptoms such as confusion, sweating, shakiness, and in severe cases, loss of consciousness or seizures. Treatment involves administering glucose or glucagon to raise blood glucose levels.
Precautions include monitoring for hypoglycemia, especially when initiating therapy or adjusting doses. Patients should be aware of symptoms of low blood sugar and know how to treat it. Caution is also advised in patients with renal or hepatic impairment, as these conditions can affect insulin metabolism and clearance.
Drug interactions may occur with medications that affect blood glucose levels, including:
Insulin Glargine should be used with caution in patients with conditions that affect glucose metabolism, such as renal or hepatic disease. Monitoring and dose adjustments may be required in these cases.
Potential drug interactions include:
Food interactions are minimal; however, maintaining a consistent eating schedule and carbohydrate intake can help prevent hypoglycemia. Alcohol consumption should be monitored as it can increase the risk of hypoglycemia.
Insulin Glargine is classified as a category C drug for pregnancy. It should be used during pregnancy only if the potential benefits outweigh the risks. Close monitoring of blood glucose levels is essential during pregnancy to ensure adequate glycemic control.
Insulin Glargine is excreted in breast milk in very small amounts. It is generally considered safe for use during lactation, but breastfeeding mothers should monitor their blood glucose levels closely and adjust insulin doses as needed.
Acute overdose of Insulin Glargine can lead to severe hypoglycemia. Symptoms may include confusion, sweating, rapid heartbeat, and in severe cases, loss of consciousness. Immediate treatment involves administering oral glucose or glucagon, and seeking emergency medical help if necessary.
Insulin Glargine is contraindicated in individuals with hypersensitivity to insulin or any of its excipients. It should not be used during episodes of hypoglycemia, and caution is advised in patients with severe renal or hepatic impairment.
Patients should follow their healthcare provider’s instructions for administering Insulin Glargine. It should be injected subcutaneously once daily, typically at the same time each day. Monitoring blood glucose levels regularly and adjusting doses based on blood glucose readings and clinical response is essential for effective management.
Store Insulin Glargine in the refrigerator (2°C to 8°C or 36°F to 46°F) until it is used. Once in use, it can be kept at room temperature (up to 25°C or 77°F) for up to 28 days. Do not freeze or expose to excessive heat or light.
The volume of distribution of Insulin Glargine is not well-documented, but it is distributed throughout the body’s tissues and fluids, similar to other insulin preparations.
The half-life of Insulin Glargine is approximately 12 to 19 hours. Its prolonged duration of action is due to its slow absorption from the subcutaneous tissue and the formation of microprecipitates.
Insulin Glargine is cleared primarily by the liver, with a small portion being excreted unchanged in the urine. The clearance rate may be influenced by liver and renal function, and dose adjustments may be required in patients with impaired organ function.
See in details version Insul Glargine SC Injection 100 IU/ml also Insul Glargine SC Injection 100 IU/ml in bangla
Insul Glargine SC Injection 100 IU/ml is a long-acting insulin analog used to manage blood sugar levels in people with diabetes.
It is used to treat both type 1 and type 2 diabetes to help control blood glucose levels.
It provides a steady release of insulin over 24 hours, helping to regulate blood sugar levels.
No, it is a long-acting insulin.
Common brand names include Lantus, Basaglar, and Toujeo.
It is injected subcutaneously (under the skin) once daily.
It is usually taken at the same time each day, either in the morning or at bedtime.
No, it should not be mixed with other insulins.
Common side effects include hypoglycemia (low blood sugar), weight gain, and injection site reactions.
It lasts approximately 24 hours.
Yes, it is approved for use in children aged 6 years and older with type 1 diabetes.
Yes, but only under a doctor's supervision.
Unopened vials should be stored in the refrigerator. Once opened, they can be kept at room temperature for up to 28 days.
No, do not freeze it. Frozen insulin should be discarded.
No, always use a new needle for each injection.
Take it as soon as possible, but do not double the dose.
Yes, weight gain is a common side effect due to improved glucose control.
Alcohol can affect blood sugar levels, so it should be consumed with caution.
Yes, hypoglycemia is a potential risk if too much insulin is taken.
Consume a fast-acting carbohydrate like glucose tablets, juice, or candy, then check your blood sugar levels.
No, rotate injection sites to avoid skin problems.
Common injection sites include the abdomen, thighs, and upper arms.
No, it starts working within a few hours and lasts up to 24 hours.
Yes, it is often used with oral diabetes medications.
No, consult your doctor before making any changes to your insulin regimen.
Yes, an overdose can cause severe hypoglycemia and requires emergency medical attention.
Yes, it is commonly used for type 1 diabetes management.
Yes, it is often prescribed for type 2 diabetes when oral medications are not sufficient.
It depends on individual needs; some people may benefit more from rapid-acting or mixed insulins.
Yes, although rare, allergic reactions such as rash, itching, or difficulty breathing may occur.
No, it is a basal insulin and should not be used for mealtime coverage.
Yes, but monitor your blood sugar levels as exercise can lower them.
Yes, but be aware of hypoglycemia symptoms while driving.
Use a backup insulin pen or vial and contact your pharmacy.
Place them in a sharps container and follow local disposal guidelines.
Yes, some medications may increase or decrease insulin effects.
Avoid excessive sugar and high-carb foods that can spike blood sugar.
At least once daily or as advised by your doctor.
Yes, but dosage adjustments may be needed.
Yes, but consult your doctor for proper dosing.
If dosed incorrectly or missed, it can lead to high blood sugar.
Some studies suggest a potential risk; consult your doctor if concerned.
Yes, carry it in a temperature-controlled bag and bring extra supplies.
Prof. Dr. Khandoker Ziaul Islam Zia
Glaucoma, Phaco, Laser & Vitreo-Retina Specialist Surgeon
Dr. A.M. Farid Uddin Ahmed
Orthopedics (Bone, Joint, Trauma, Spine) Specialist & Surgeon